According to Zhitong Finance App News, Wantai Biotech (603392.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1,048 billion yuan, an increase of 24.29%; net profit loss attributable to shareholders of listed companies was 128 million yuan, a year-on-year narrowing; loss after deducting non-net profit of 169 million yuan, a year-on-year narrowing; and basic earnings per share were -0.10 yuan.

The increase in revenue is mainly due to the continuous promotion of terminal access sales volume after the launch of the nine-valent HPV vaccine. The vaccine sector's revenue increased compared to the same period last year. Net profit attributable to shareholders of listed companies narrowed compared to losses in the same period last year due to the factors affecting operating income described above.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.